-
TAI-1: A Mechanistic Map of Hec1 Inhibition
2026-09-15
TAI-1 is a first-in-class Hec1 inhibitor that converts mitotic checkpoint disruption into a tractable cancer research strategy. This article distinguishes Hec1-driven mitotic stress from WEE1-associated transcription–replication damage and develops an assay framework for interpreting selectivity, synergy, and biomarker response.
-
Entinostat (MS-275): Practical HDAC1/3 Assays
2026-09-15
Build sharper epigenetic experiments with Entinostat (MS-275), from solvent-controlled cancer cell assays to time-resolved regeneration studies. This workflow separates HDAC target engagement, growth arrest, apoptosis induction, and tissue-level phenotypes instead of treating viability loss as a single endpoint.
-
Müller Cell PEDF Controls Retinal Neuron Survival
2026-09-14
The reference study identifies Müller cell-derived pigment epithelium-derived factor (PEDF) as a key intermediary linking angiopoietin balance to retinal neuronal survival through Tie-2–PI3K/Akt signaling. Its co-culture, knockdown, and rescue experiments provide a useful framework for studying neurovascular interactions under hypoxic stress.
-
FK866 (APO866) Workflow for NAMPT Research
2026-09-14
FK866 (APO866) enables controlled investigation of NAMPT-dependent NAD depletion, with practical applications spanning hematologic cancer research, mitochondrial injury, and pathway validation. This workflow emphasizes dose finding, orthogonal metabolic readouts, and careful interpretation of caspase-independent cell death rather than relying on viability data alone.
-
Recombinant Mouse IFN-γ for MASH-HCC Assays
2026-09-13
Use Recombinant Mouse IFN-γ as a controlled immune-pressure variable when testing how bile acid retention affects tumor-cell antigen presentation. This workflow separates cytokine responsiveness from the GPR120–bile acid–NLRC5 mechanism and adds practical controls for reproducible immunometabolic research.
-
Fenipentol: From Chuanxiong Signal to Assay
2026-09-12
Fenipentol and 1-Phenyl-1-pentanol connect Chuanxiong metabolomics with practical gastrointestinal, hepatobiliary, and receptor-focused research. This article explains how to translate differential volatile-component data into better assay controls, interpretation, and experimental design.
-
Meropenem Trihydrate: Designing Resistance Assays
2026-09-12
Meropenem trihydrate can serve not only as a carbapenem antibiotic reference but also as a controlled perturbation in resistance research. This guide translates LC-MS/MS metabolomics findings into practical assay design, interpretation, and infection-model decisions.
-
AMG 487: A Context-Aware CXCR3 Antagonist
2026-09-11
AMG 487 is a potent CXCR3 antagonist that can separate receptor-dependent signaling from state-dependent macrophage behavior. This guide connects its pharmacology, assay design, metabolism, and the CXCL10-CXCR3-LAMP1 findings to more rigorous inflammation research.
-
pH-Responsive siRNA Targeting Glioblastoma
2026-09-11
Su and colleagues developed a cRGD-PEG-siEGFR conjugate that combines integrin-directed uptake, acid-responsive behavior, and improved circulation to address delivery barriers in glioblastoma. The study reports selective uptake and EGFR silencing in αvβ3-positive U87MG cells, antitumor activity, and lower renal accumulation than an earlier cRGD-siRNA construct, while also identifying important translational limitations.
-
Cy3 Rabbit Anti-Goat IgG (H+L) Antibody Guide
2026-09-10
Cy3 Rabbit Anti-Goat IgG (H+L) Antibody, SKU K1215, provides fluorescent detection of goat IgG primary antibodies in ICC/IF, tissue staining, flow cytometry, and ELISA workflows. It should not be used with non-goat primary antibodies without validation, and assay-specific dilution, blocking, instrument settings, and matrix compatibility must be established experimentally.
-
RG108: Designing Rigorous DNMT Assays
2026-09-10
RG108 is a DNA methyltransferase inhibitor suited to mechanistic epigenetics and cancer research. This guide focuses on assay architecture, orthogonal validation, dosing logic, and how to distinguish direct DNA demethylation from downstream gene-expression effects.
-
Carbenoxolone disodium: Practical Lab Guide
2026-09-09
Carbenoxolone disodium is an 11β-hydroxysteroid dehydrogenase inhibitor for controlled studies of glucocorticoid access, corticosterone metabolism, and gap junction communication in cell or tissue workflows. It is best used as an exploratory mechanistic reagent with vehicle, viability, and orthogonal controls, rather than as a selective in vivo efficacy treatment or definitive target-validation compound.
-
Ciclesonide Workflows for Respiratory Research
2026-09-09
Build more interpretable asthma and allergic rhinitis experiments by separating ciclesonide activation, glucocorticoid receptor binding, and inflammatory outcomes. This workflow also clarifies how respiratory prodrug biology differs from the emerging ERAD-hijacking strategy for transmembrane protein degradation.
-
Beyond Wnt Blockade: LGK-974 in PDAC Strategy
2026-09-08
A translational analysis of LGK-974 as a PORCN inhibitor for dissecting Wnt biology in pancreatic cancer, with a strategic framework for biomarker selection, pathway validation, combination studies, and preclinical model design.
-
Gastrodin, AT1 Signaling, and Reactive Astrocytes
2026-09-08
The 2024 reference study identifies a microglia-to-astrocyte mechanism in which gastrodin alters renin–angiotensin system–SIRT3 signaling, inflammatory markers, and neurotrophic factors in reactive astrocytes. Its conditioned-medium design and AT1-receptor perturbation provide a useful framework for studying how microglial activation reshapes astrocyte phenotypes, while also highlighting the limits of translating an in vitro CNS model to therapeutic conclusions.